| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10557-015-6605-6 |
| P8608 | Fatcat ID | release_c2f6rwqsuffunfagbr52rerrjy |
| P698 | PubMed publication ID | 26145170 |
| P5875 | ResearchGate publication ID | 279808373 |
| P50 | author | Rosalinda Madonna | Q83194522 |
| Raffaele De Caterina | Q87797284 | ||
| Nino Cocco | Q114521091 | ||
| P2860 | cites work | Treatment goals of pulmonary hypertension | Q26851767 |
| Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning | Q26995004 | ||
| Endothelin system: the double-edged sword in health and disease | Q28206380 | ||
| End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? | Q33476711 | ||
| Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis | Q33715766 | ||
| Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study | Q33834751 | ||
| Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension | Q34002038 | ||
| Endothelial dysfunction in pulmonary hypertension | Q34291213 | ||
| Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension | Q34294101 | ||
| Survival with first-line bosentan in patients with primary pulmonary hypertension. | Q34389894 | ||
| Definitions and diagnosis of pulmonary hypertension. | Q34393150 | ||
| Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. | Q34424315 | ||
| Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension | Q34985266 | ||
| Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In | Q34999923 | ||
| Die pulmonale Hypertonie – historische Entwicklung, derzeitiger Stand der Therapie und Ausblick | Q57824113 | ||
| Pulmonary Arterial Hypertension | Q58485998 | ||
| Endothelin-1 in the lungs of patients with pulmonary hypertension | Q58622178 | ||
| Contribution of endogenous generation of endothelin-1 to basal vascular tone | Q58656776 | ||
| Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol | Q35537385 | ||
| Apelin and pulmonary hypertension. | Q35573931 | ||
| Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy | Q35792872 | ||
| Cellular and molecular pathobiology of pulmonary arterial hypertension | Q35803229 | ||
| Altered expression and signal transduction of endothelin-1 receptors in heritable and idiopathic pulmonary arterial hypertension | Q36394025 | ||
| Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension | Q36411409 | ||
| Relaxation of human pulmonary arteries by PPARγ agonists. | Q36755896 | ||
| Modern age pathology of pulmonary arterial hypertension | Q37457479 | ||
| End points and clinical trial design in pulmonary arterial hypertension | Q37531281 | ||
| The role of the right ventricle in pulmonary arterial hypertension | Q37963253 | ||
| Nanoparticle-mediated treatment of pulmonary arterial hypertension | Q37997222 | ||
| Challenges in the diagnosis and treatment of pulmonary arterial hypertension | Q38064384 | ||
| Combination therapy in the management of pulmonary arterial hypertension | Q38098260 | ||
| Updated treatment algorithm of pulmonary arterial hypertension. | Q38172728 | ||
| Endothelial-like progenitor cells engineered to produce prostacyclin rescue monocrotaline-induced pulmonary arterial hypertension and provide right ventricle benefits | Q38488215 | ||
| Inhibition of vascular endothelial growth factor receptor under hypoxia causes severe, human-like pulmonary arterial hypertension in mice: potential roles of interleukin-6 and endothelin | Q39035506 | ||
| Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist | Q39941733 | ||
| Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension | Q39993104 | ||
| An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension | Q41123021 | ||
| The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension | Q41768885 | ||
| Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension | Q42407453 | ||
| Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension | Q43117862 | ||
| Role of epidermal growth factor inhibition in experimental pulmonary hypertension. | Q43256381 | ||
| Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study | Q43764381 | ||
| Macitentan and morbidity and mortality in pulmonary arterial hypertension | Q44343572 | ||
| Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. | Q44478379 | ||
| Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. | Q45052802 | ||
| Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance | Q46106049 | ||
| Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. | Q46484459 | ||
| Unlooked-for significance of cardiac versus vascular effects of endothelin-1 in the pathophysiology of pulmonary arterial hypertension | Q46493825 | ||
| Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. | Q46573264 | ||
| Ambrisentan therapy for pulmonary arterial hypertension | Q46626290 | ||
| Goal-oriented treatment and combination therapy for pulmonary arterial hypertension | Q46786766 | ||
| The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries | Q47381547 | ||
| Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. | Q47823670 | ||
| Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. | Q48385253 | ||
| Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. | Q48699378 | ||
| Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. | Q51295363 | ||
| Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levels | Q54157002 | ||
| Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. | Q54237894 | ||
| Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. | Q54247452 | ||
| High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. | Q54285255 | ||
| Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? | Q54299949 | ||
| Do Changes of 6-Minute Walk Distance Predict Clinical Events in Patients With Pulmonary Arterial Hypertension? | Q57618842 | ||
| P433 | issue | 5 | |
| P921 | main subject | arterial hypertension | Q41861 |
| P304 | page(s) | 469-479 | |
| P577 | publication date | 2015-07-07 | |
| P1433 | published in | Cardiovascular Drugs and Therapy | Q2473050 |
| P1476 | title | Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists | |
| P478 | volume | 29 |
| Q38976589 | Aerobic exercise-related attenuation of arterial pulmonary hypertension: A right arrow targets the disease? |
| Q37539466 | Aldehyde dehydrogenase 2 protects against oxidative stress associated with pulmonary arterial hypertension |
| Q52731057 | COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? (2017 Grover Conference Series). |
| Q38562801 | Epigenetic regulation of insulin-like growth factor signaling: A novel insight into the pathophysiology of neonatal pulmonary hypertension. |
| Q41571586 | Pharmacokinetic study of ACT-132577 in rat plasma by ultra performance liquid chromatography-tandem mass spectrometry |
Search more.